Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST Form 4 June 24, 201:	PHARMACEUT	ICALS I	NC								
FORM	1 4									PROVAL	
-	UNITEDS	Washington, D.C. 20549								3235-0287	
Check thi if no long subject to Section 1 Form 4 or Form 5 obligation	 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, 							burden hou response	Estimated average burden hours per response 0.1		
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section See Instruction 1(b).											
(Print or Type F	Responses)										
STAAB THOMAS R II Sym BIG			Symbol	Name and YST PHA				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (M	liddle)	3. Date of	Earliest Tra	ansaction			Director		Owner	
			(Month/D 06/22/20	-				XOfficer (give titleOther (specify below) Senior Vice President and CFO			
				ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
DURHAM, NC 27703								Form filed by More than One Reporting Person			
(City)	(State) (Zip)	Table	e I - Non-De	erivative S	Securi	ities Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		Transaction Date 2A. Deemed 3. 4. Securities Acquin Ionth/Day/Year) Execution Date, if any Code (D) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)		d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)					
Comm				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock (1)	06/22/2015			М	3,750	А	\$ 4.73	149,894	D		
Common Stock (1)	06/22/2015			S	3,750	D	\$ 16	146,144	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (,
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Emp. Stock Option (Right to Buy) (1)	\$ 4.73	06/22/2015		М	3	8,750	03/01/2013	03/01/2022	Common Stock	3,750	

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703			Senior Vice Presid	lent and CFO				
Signatures								
/s/ Alane P. Barnes, by power of attorney	of	06/24	/2015					

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 D S (]